Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•5 min read

    What Is Erythropoietin? Benefits, Research & Safety

    A glycoprotein hormone that stimulates red blood cell production, used medically to treat anaemia.

    Share:X PostLinkedIn
    Also known as:
    EPO
    Epoetin
    AStrong human evidenceUK: Prescription-only (UK POM)WADA: Prohibited in sport

    UK summary: UK prescription-only medicine for chronic-kidney-disease anaemia and certain chemotherapy-induced anaemia. Famously misused for blood doping; prohibited under WADA S2. Several documented deaths linked to athlete abuse.

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Epoetin alfa: 4-13 hours IV, 19-24 hours SC; Darbepoetin alfa: 21-25 hours IV, 46-70 hours SC
    UK Status
    Prescription-only medicine. Multiple EPO products approved for specific anaemia indications. MHRA-regulated.
    EU Status
    Approved for anaemia in CKD, cancer treatment, autologous blood donation programs. EMA-regulated.

    Overview

    Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys that plays a central role in regulating red blood cell (erythrocyte) production—a process known as erythropoiesis. When oxygen levels in the blood drop, the kidneys release EPO, which travels to the bone marrow and stimulates the production and maturation of red blood cells. Recombinant human erythropoietin (rHuEPO) was one of the first successful applications of biotechnology in medicine, revolutionising the treatment of anaemia in patients with chronic kidney disease, cancer patients undergoing chemotherapy, and other conditions affecting red blood cell production. EPO became infamous in sports due to its blood-doping effects—increasing oxygen-carrying capacity and endurance. It remains a prohibited substance under WADA regulations and has been central to numerous doping scandals. **Regulatory Status:** EPO products (epoetin alfa, epoetin beta, darbepoetin alfa) are approved prescription medications for specific indications including renal anaemia and chemotherapy-induced anaemia.
    Evidence standards summary

    Erythropoietin — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    AStrong human evidenceOverall grade against our evidence grading methodology.

    UK prescription-only medicine for chronic-kidney-disease anaemia and certain chemotherapy-induced anaemia. Famously misused for blood doping; prohibited under WADA S2. Several documented deaths linked to athlete abuse.

    02Human evidence grade

    AStrong human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Prescription-only medicine. Multiple EPO products approved for specific anaemia indications. MHRA-regulated.
    • EU: Approved for anaemia in CKD, cancer treatment, autologous blood donation programs. EMA-regulated.
    • Notes: EPO is a legitimate, approved medication for treating anaemia but is strictly prohibited in sport. WADA has developed sophisticated detection methods including the EPO urine test and biological passport. Misuse for performance enhancement is dangerous and can be fatal.

    05Approved medical uses

    • Anaemia of chronic kidney disease (epoetin alfa / beta — MHRA-licensed POM).
    • Chemotherapy-induced anaemia.
    • Selected myelodysplastic syndromes.

    06Unapproved / promotional claims

    • EPO is safe for athletes if monitored.
    • Microdosing EPO is undetectable.

    07Common internet claims

    • Endurance-athlete doping market; supply via grey-market vendors.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “EPO is safe for athletes if monitored”ENoHighAthlete EPO use carries documented mortality risk (blood clots, stroke, sudden death) and is prohibited under WADA. Strict liability applies.

    09Safety uncertainty score

    Very high

    Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.

    10Known adverse signals

    • Polycythaemia / blood viscosity / stroke / pulmonary embolism / sudden death.
    • Documented athlete deaths from misuse over decades.
    • Hypertension, headaches.
    • Antibody formation (pure red cell aplasia, rare but serious).

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Prescription-only (UK POM)

    Prescription-only medicine. Multiple EPO products approved for specific anaemia indications. MHRA-regulated.

    Read the full UK legal guide → Peptides and athletes (UK)

    14EU legal position

    Approved for anaemia in CKD, cancer treatment, autologous blood donation programs. EMA-regulated.

    15What this page cannot tell you

    • Whether a grey-market EPO product contains the labelled compound or has been adulterated.
    • Whether 'microdose' protocols are truly undetectable (assume not — Athlete Biological Passport tracks erythropoietic markers).

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Athlete-misuse harms are documented; no legitimate research basis for healthy-adult EPO use.

    19Safer alternatives / established care pathways

    • NHS anaemia investigation via GP (iron studies, B12, folate, thyroid).
    • Treatment of underlying cause where identified.
    • Endurance training is the lawful and safe performance-enhancement route.

    Related Safety Centre page → Athlete anti-doping risks

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • If I have anaemia, what NHS investigation pathway is appropriate?

    Discovery & History

    The existence of a humoral factor controlling red blood cell production was first proposed in the early 20th century. The term "erythropoietin" was coined in 1948 by Eva Bonsdorff and Eeva Jalavisto. Key milestones in EPO history: **1950s-1960s:** Researchers confirmed EPO's existence and its renal origin. Allan Erslev demonstrated that plasma from anaemic animals could stimulate red cell production in normal animals. **1977:** EPO was purified from human urine by Takaji Miyake and Eugene Goldwasser, yielding milligram quantities from thousands of litres of urine from patients with aplastic anaemia. **1983:** The EPO gene was cloned by Fu-Kuen Lin at Amgen, enabling recombinant production. **1989:** The FDA approved epoetin alfa (Epogen/Procrit) for treating anaemia in chronic kidney disease patients—one of the first major biotechnology drugs. **1990s-2000s:** EPO's misuse in sports became widespread, particularly in cycling. The death of several cyclists was linked to EPO abuse. This led to the development of EPO detection tests. **2000s-present:** Longer-acting erythropoiesis-stimulating agents (ESAs) were developed (darbepoetin alfa, CERA). Safety concerns emerged about target haemoglobin levels, leading to revised dosing guidelines.

    Mechanism of Action

    Erythropoietin exerts its effects through a well-characterised receptor-mediated pathway: **EPO Receptor Binding** EPO binds to the erythropoietin receptor (EPOR) on the surface of erythroid progenitor cells in the bone marrow: - EPOR is a type I cytokine receptor - Binding causes receptor dimerization and conformational change - Activates associated JAK2 (Janus kinase 2) **JAK-STAT Signaling** The primary signaling pathway: - JAK2 phosphorylates STAT5 transcription factors - Activated STAT5 translocates to the nucleus - Induces transcription of anti-apoptotic genes (Bcl-xL) - Promotes survival and proliferation of erythroid progenitors **Erythropoiesis Stimulation** Effects on red blood cell production: - Prevents apoptosis of CFU-E and proerythroblasts - Accelerates maturation of erythroid precursors - Increases reticulocyte release from bone marrow - Results in elevated red blood cell count and haemoglobin **Oxygen-Sensing Regulation** How the body controls EPO production: - Hypoxia-inducible factors (HIF) sense low oxygen - HIF-2α activates EPO gene transcription in kidneys - Increased oxygen suppresses EPO production - Creates a negative feedback loop maintaining homeostasis **Non-Erythroid Effects** EPO receptors exist in other tissues: - Neuroprotective effects (brain) - Cardioprotective effects (heart) - Wound healing effects - These are areas of ongoing research

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Treatment of anaemia in chronic kidney disease (approved indication)
    • 2
      Management of chemotherapy-induced anaemia (approved indication)
    • 3
      Reduction in blood transfusion requirements
    • 4
      Improvement in quality of life and exercise tolerance in anaemic patients
    • 5
      Treatment of anaemia in HIV/AIDS patients on zidovudine (approved indication)
    • 6
      Potential neuroprotective effects (research ongoing)

    Claim vs Evidence

    How popular claims about Erythropoietin stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “EPO is safe for athletes if monitored”ENoHighAthlete EPO use carries documented mortality risk (blood clots, stroke, sudden death) and is prohibited under WADA. Strict liability applies.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageVaries by indication: typically 50-300 IU/kg three times weekly for renal anaemia
    Frequency1-3 times weekly depending on product (epoetin alfa/beta) or once weekly to every 2 weeks (darbepoetin alfa)
    DurationOngoing treatment as long as anaemia persists and benefit continues
    NotesEPO is a prescription medication that requires medical supervision and regular monitoring of haemoglobin, iron status, and blood pressure. Target haemoglobin levels should be individualised. Off-label or athletic use is dangerous and illegal.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (preferred for CKD patients not on dialysis)
    • Intravenous injection (common for dialysis patients)
    Half-LifeStability
    Epoetin alfa: 4-13 hours IV, 19-24 hours SC; Darbepoetin alfa: 21-25 hours IV, 46-70 hours SCRequires refrigeration (2-8°C); do not freeze; protect from light

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Hypertension (most common and significant)
    • Headache
    • Flu-like symptoms
    • Injection site reactions
    • Arthralgia
    • Nausea

    Rare Risks & Concerns

    • Pure red cell aplasia (PRCA) with anti-EPO antibodies (rare but serious)
    • Thromboembolic events (stroke, MI, DVT)
    • Progression of certain tumours (controversial)
    • Seizures
    • Severe hypertension and hypertensive encephalopathy

    Contraindications

    • Uncontrolled hypertension
    • Known hypersensitivity to EPO products
    • Pure red cell aplasia following EPO treatment
    • Use with target haemoglobin >12 g/dL in cancer patients (FDA warning)

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Prescription-only medicine. Multiple EPO products approved for specific anaemia indications. MHRA-regulated.

    🇪🇺 European Union

    Approved for anaemia in CKD, cancer treatment, autologous blood donation programs. EMA-regulated.

    EPO is a legitimate, approved medication for treating anaemia but is strictly prohibited in sport. WADA has developed sophisticated detection methods including the EPO urine test and biological passport. Misuse for performance enhancement is dangerous and can be fatal.

    Clinical Studies Summary

    A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

    Large trial in diabetic CKD patients showing darbepoetin increased stroke risk when targeting normal haemoglobin levels.

    N Engl J Med. 2009View on PubMed

    Correction of anemia with epoetin alfa in chronic kidney disease.

    Study showing increased cardiovascular risk with higher haemoglobin targets in CKD patients on epoetin alfa.

    N Engl J Med. 2006View on PubMed

    Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

    European trial examining early vs late EPO use in CKD, contributing to haemoglobin target guidelines.

    N Engl J Med. 2006View on PubMed

    Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis.

    Daprodustat and roxadustat indicated equivalent or higher efficacy when compared to darbepoetin in elevating hemoglobin levels in CKD-related anemia, with daprodustat demonstrating a good safety profile. While conventional ESAs remain beneficial, HIF-PHIs offer promising oral alternatives with possible benefits in cardiovascular safety and decreased hypertension risk.

    BMC Nephrol. 2025View on PubMed

    Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.

    92]) from baseline values. Dialysis-dependent patients with anemia had a significant increment in serum Hemoglobin and TIBC and a reduction in serum ferritin, in a dose-dependent manner, when administered daprodustat.

    Pan Afr Med J. 2024View on PubMed

    Evaluating the Safety and Efficacy of Erythropoietin Therapy for Neonatal Hypoxic-Ischemic Encephalopathy: A Systematic Review and Meta-Analysis.

    The results of our meta-analysis do not support the use of EPO for the treatment of neonatal encephalopathy. However, future large-scale RCTs are needed to strengthen these findings.

    Pediatr Neurol. 2024View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    74
    Currently recruiting
    2
    Furthest phase
    Phase 4
    Approved product
    Yes
    PROCRIT

    34 of 43 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

    PHASE3

    Status: Not Yet Recruiting · 100 participants · Geoff Block

    Conditions: Anemia Associated With Chronic Kidney Disease

    No results postedNCT07565701

    EVR and EPO for Liver Transplant Tolerance

    PHASE1

    Status: Recruiting · 20 participants · National Institute of Allergy and Infectious Diseases (NIAID)

    Conditions: Liver Transplant

    No results postedNCT06832189

    " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

    N/A

    Status: Not Yet Recruiting · 66 participants · Fayoum University

    Conditions: Erythropoietin Resistant Anemia (EPO Resistant Anemia)

    No results postedNCT06983756

    Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia

    NA

    Status: Unknown · 419 participants · West China Hospital

    Conditions: Total Knee Arthroplasty

    No results postedNCT05911438

    Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

    PHASE4

    Status: Active Not Recruiting · 9 participants · Northwestern University

    Conditions: Liver Transplant Rejection

    No results postedNCT05325073

    Practical Anemia Bundle for SusTained Blood Recovery

    PHASE2

    Status: Completed · 100 participants · Mayo Clinic

    Conditions: Anemia, Critical Illness

    Results postedNCT05167734

    Mechanisms of EPO-induced Hypertension

    PHASE2

    Status: Terminated · 27 participants · VA Office of Research and Development

    Conditions: Chronic Kidney Disease, Blood Pressure, Anemia

    Results postedNCT03810911

    ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

    PHASE3

    Status: Recruiting · 2,500 participants · Australian and New Zealand Intensive Care Research Centre

    Conditions: Trauma, Traumatic Injury, Traumatic Brain Injury

    No results postedNCT04588311

    Exosome Proteomics to Detect EPO

    NA

    Status: Unknown · 72 participants · Morten Hostrup, PhD

    Conditions: Healthy

    No results postedNCT03700515

    CD71 in Dried Blood Spots in Healthy Males

    EARLY_PHASE1

    Status: Completed · 24 participants · Sports Medicine Research and Testing Laboratory

    Conditions: Healthy Athletes

    No results postedNCT04073849

    Combination Therapy of Umbilical Cord Blood and Erythropoietin for Stroke Paients

    PHASE1/PHASE2

    Status: Unknown · 24 participants · Bundang CHA Hospital

    Conditions: Stroke, Umbilical Cord Blood, Erythropoietin

    No results postedNCT04013646

    Evening Primrose Oil Efficacy in Second Trimester Abortion

    PHASE3

    Status: Unknown · 100 participants · Ain Shams University

    Conditions: Missed Abortion

    No results postedNCT03698734

    Adverse event reports (FDA FAERS)

    • anaemia553
    • haemoglobin decreased337
    • off label use324
    • pneumonia315
    • diarrhoea292
    • death285
    • pyrexia259
    • thrombocytopenia259
    • neutropenia240
    • fatigue234

    FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for Erythropoietin?

    Source research-grade Erythropoietin from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Erythropoietin

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • If I have anaemia, what NHS investigation pathway is appropriate?

    UK regulatory & safety context

    Peptides and athletes (UK)

    UK legal reference

    Athlete anti-doping risks

    Safety Centre guide

    Related Peptides

    HGH Fragment 176-191

    A fragment of human growth hormone corresponding to amino acids 176-191, researched specifically for its fat-metabolising properties.

    Learn more

    IGF-1 LR3

    A modified, highly potent analogue of insulin-like growth factor 1 with extended half-life and reduced binding protein affinity.

    Learn more

    ACTH

    A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.